Henry Waxman speaks about Hatch-Waxman Act at GPhA’s meeting
NAPLES, Fla. Appearing via video at the Generic Pharmaceutical Association’s annual meeting in Naples, Fla., to celebrate the 25th anniversary of the Hatch-Waxman Act that he helped write, Democratic California Rep. Henry Waxman said that the market exclusivity model in the Hatch-Waxman Act would work well for biosimilars.
“One of the biggest sticking points in the debate over biogeneric legislation will be the number of years of exclusivity to which brand companies are entitled,” Waxman said in video remarks. “The brand industry is calling for 12, 14, 16 and even 20 years of exclusivity. It makes my head spin trying to keep up with their ever-changing arguments for why these terms are justified.”
In a panel discussion with GPhA president and CEO Kathleen Jaeger, Biotechnology Industry Organization president and CEO Jim Greenwood said there should be follow-on biologics, that they can be safe and effective and produce competition and savings, but reiterated BIO’s position calling for 14 years of market exclusivity. The Hatch-Waxman Act allows a five-year exclusivity period for new drugs.
Still, Greenwood said he was confident that the generic drug and biotech industries would “find enough common ground to serve patients.”
Walgreens’ Take Care opens new Memphis-area clinic
CONSHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has opened a new clinic in the Memphis area, bringing the number of clinics in that market to nine.
The company now operates 331 clinics in 35 markets throughout 19 states.
Etreby adds Rx-Net VSR pricing software to list of supported pharmacy software packages
BLOOMINGDALE, Ill. The Etreby Systems association has added a pharmacy operating system to its list of supported pharmacy software packages.
Rx-Net announced last week that its VSR drug pricing software package runs on Etreby, along with RX30, HBS, Liberty Rxite Quick, Cost Effective, Compusolve, PK Software and Pharmaserv.
VSR automatically populates prices up to 2,100 of the most popular branded and generic drugs with pricing data updated monthly from other, nearby stores. Rx-Net said the software allows pharmacies the flexibility to exclude certain drugs from pricing, adjust percentages and overrides to suit the local market and clientele.
“Now that we’ve branched out into a broader base of popular pharmacy systems, we can offer the ability of a larger base of pharmacists to deliver more effective health care to their customers by freeing up the time usually spent doing pricing research and dealing with the complications of third-party issues,” Rx-Net president Michael Cannata stated.